Study program | Treatment group | North America | Western Europe | Australia/South Africa | Japan | Asia | Eastern Europe/Russia | South America/Mexico |
---|---|---|---|---|---|---|---|---|
IDENTITY | Placebo | 0.52 ± 1.31SA,EE,JP | 0.37 ± 0.78EE,JP | 0.34 ± 0.48 | 0.14 ± 0.17 WE,NA | 0.31 ± 0.63 | 0.31 ± 0.84WE,NA | 0.25 ± 0.56NA |
Semagacestat 140 mg PO | 1.10 ± 1.59EE,JP | 0.76 ± 1.02EE | 0.87 ± 0.85EE | 0.57 ± 0.86NA | 0.69 ± 0.89 | 0.62 ± 1.28AU,WE,NA | 0.88 ± 1.36 | |
EXPEDITION | Placebo | 0.40 ± 0.57SA,EE,JP,WE | 0.24 ± 0.27SA,EE,NA | 0.42 ± 0.31SA,EE, JP,WE | 0.16 ± 0.13AU,NA | 0.31 ± 0.42EE | 0.19 ± 0.40AS,AU,WE,NA | 0.22 ± 0.28AU,NA |
Solanezumab 400 mg IV | 0.41 ± 0.68SA,EE,JP,WE | 0.24 ± 0.63NA | 0.51 ± 1.04SA,EE | 0.21 ± 0.22NA | 0.29 ± 0.68EE | 0.11 ± 0.13AS,AU,NA | 0.19 ± 0.29AU,NA |